These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27017752)

  • 1. [EFFECTS OF URSODEOXYCHOLIC ACID IN STANDART INTERFERONTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS C AND B].
    Kurmanova GM; Kurmanova KB; Sadykova ShS
    Eksp Klin Gastroenterol; 2015; (8):99-104. PubMed ID: 27017752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C.
    Taskoparan M; Serin E; Gokturk HS; Icer MO; Abaci K; Ozer B; Zumrutdal A; Yilmaz U
    Hepatogastroenterology; 2011; 58(107-108):875-9. PubMed ID: 21830408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy effects upon hepatitis C cholestatic syndrome.
    Vere CC; Gofiţă E; Forţofoiu C; Streba LA; Genunche A
    Rom J Morphol Embryol; 2007; 48(1):51-4. PubMed ID: 17502951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Kronenberger B; Herrmann E; Micol F; von Wagner M; Zeuzem S
    Hepatology; 2004 Dec; 40(6):1442-9. PubMed ID: 15565603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Puoti C; Bellis L; Castellacci R; Montagnese F
    Hepatology; 2005 Mar; 41(3):683; author reply 684. PubMed ID: 15723301
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
    J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of combination therapy with peginterferon alfa-2alpha and bicyclol in chronic hepatitis B with high ALT levels].
    Ni Q; Tian-Sheng X; Min-Wei L; Ke-Zhou L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Apr; 26(2):114-6. PubMed ID: 23002549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial.
    Kiso S; Kawata S; Tamura S; Imai Y; Inui Y; Nagase T; Maeda Y; Yamasaki E; Tsushima H; Igura T; Himeno S; Seki K; Matsuzawa Y
    J Gastroenterol; 1997 Feb; 32(1):56-62. PubMed ID: 9058296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of diphenyl-dimethyl-dicarboxylate plus garlic oil in patients with chronic hepatitis.
    Lee MH; Kim YM; Kim SG
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):778-86. PubMed ID: 22943930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C].
    Yu J; Liu BW; Lan L; Yuan Y; Zhang H; Jia CH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Oct; 24(5):373-5. PubMed ID: 21280329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
    Kowala-Piaskowska A; Mozer-Lisewska I; Figlerowicz M; Słuzewski W
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1095-103. PubMed ID: 17724740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.